Ropes & Gray represented Black Diamond Therapeutics in a global licensing agreement with French pharmaceutical company Servier for the development and commercialization of BDTX-4933, a therapy designed to target RAS and RAF alterations in solid tumors. The collaboration aims to advance the asset across multiple indications, including non-small cell lung cancer and other solid tumors. The agreement was announced on March 19.
Under the agreement, Servier will be responsible for the global development and commercialization of BDTX-4933. Black Diamond will receive an upfront payment of $70 million and is eligible for up to $710 million in milestone payments, along with tiered royalties on global net sales.
The Ropes & Gray team was led by life sciences licensing partner Abigail Gregor and IP transactions associate Esteban De La Torre and included litigation & enforcement partner Lisa Kaltenbrunner and litigation & enforcement associate Vincenzo Volpe.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.